Direct-acting antiviral (DAA) treatment reduces fibrotic disease burden in patients with hepatitis C virus infection. (IMAGE)

Korea University College of Medicine

Direct-acting antiviral (DAA) treatment reduces fibrotic disease burden in patients with hepatitis C virus infection.

Caption

Researchers from multiple institutions across South Korea collected individual participant data from the medical records of patients with hepatitis C virus infection, treated with direct-acting antivirals. They compared liver fibrosis, a key feature of disease severity, and liver-related clinical outcomes of untreated group with the DAA group.

Credit

Associate Prof. Seungbong Han from Korea University

Usage Restrictions

Cannot be reused without permission

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.